Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 21
Filtre
Ajouter des filtres








Gamme d'année
1.
Indian J Dermatol Venereol Leprol ; 2018 May; 84(3): 353-354
Article | IMSEAR | ID: sea-192362
2.
Indian J Dermatol Venereol Leprol ; 2018 Jan; 84(1): 49-53
Article | IMSEAR | ID: sea-192346

Résumé

Background: Targeted phototherapy is a recent advance in the treatment of vitiligo, involving selective treatment of vitiligo patches with no effect on surrounding areas. Although it has been in use for a few years, little data is available regarding its safety and efficacy. Aims: A retrospective study to determine efficacy and safety of targeted phototherapy in vitiligo. Methods: One hundred and thirty four patients (male: 53, female: 81) who received targeted phototherapy and completed 11 or more sittings were included. Treatment was given once a week using the Lumera phototherapy system, a broadband ultraviolet B source, starting at 150 mJ/spot and after excluding a sunburn reaction, with increments of 50 mJ every week up to a maximum of 1000 mJ/patch. Chi-square test for linear trends was used for statistical analysis. Results: The most common sites involved were the legs and a majority (70.9%) had non-segmental vitiligo. Response was mild in 78 (58.2%) patients, moderate in 50 (37.3%) and excellent in 6 (4.5%) patients. Response was directly proportional to the number of sittings with more patients showing moderate and excellent responses with an increase in the number of sittings. The most common site for an excellent response was the trunk while the lower limbs were involved in most cases with a moderate or mild response. Side effects were seen in 27 (20.2%) patients, the commonest being erythema. Limitations: This is a retrospective uncontrolled study. Further, the effects of adjuvant treatment were not assessed. Conclusions: Targeted phototherapy is a useful treatment for vitiligo with mild adverse effects, though response is mild or moderate and appears to be directly proportional to the number of treatments received.

3.
Indian J Dermatol Venereol Leprol ; 2017 Jan-Feb; 83(1): 137-143
Article Dans Anglais | IMSEAR | ID: sea-183442
4.
Indian J Dermatol Venereol Leprol ; 2016 Nov-Dec; 82(6): 745-751
Article Dans Anglais | IMSEAR | ID: sea-178532
5.
Indian J Dermatol Venereol Leprol ; 2016 Sept-Oct; 82(5): 589-594
Article Dans Anglais | IMSEAR | ID: sea-178492
6.
Indian J Dermatol Venereol Leprol ; 2016 July-Aug; 82(4): 468- 473
Article Dans Anglais | IMSEAR | ID: sea-178455
7.
Indian J Dermatol Venereol Leprol ; 2016 May-June; 82(3): 360
Article Dans Anglais | IMSEAR | ID: sea-178226
8.
Indian J Dermatol Venereol Leprol ; 2016 Mar-Apr; 82(2): 240-245
Article Dans Anglais | IMSEAR | ID: sea-178190
9.
Indian J Dermatol Venereol Leprol ; 2016 Jan-Feb; 82(1): 114-119
Article Dans Anglais | IMSEAR | ID: sea-170091
10.
Indian J Dermatol Venereol Leprol ; 2015 Nov-Dec; 81(6): 657
Article Dans Anglais | IMSEAR | ID: sea-169942
11.
Indian J Dermatol Venereol Leprol ; 2015 Sept-Oct; 81(5): 550-555
Article Dans Anglais | IMSEAR | ID: sea-169789
13.
Indian J Dermatol Venereol Leprol ; 2015 May-Jun; 81(3): 329-333
Article Dans Anglais | IMSEAR | ID: sea-158355
14.
Indian J Dermatol Venereol Leprol ; 2015 Mar-Apr; 81(2): 226-230
Article Dans Anglais | IMSEAR | ID: sea-158371
16.
Indian J Dermatol Venereol Leprol ; 2014 Nov-Dec; 80(6): 583-587
Article Dans Anglais | IMSEAR | ID: sea-154947
17.
Indian J Dermatol Venereol Leprol ; 2011 Sept-Oct; 77(5): 591-593
Article Dans Anglais | IMSEAR | ID: sea-140926
18.
Indian J Dermatol Venereol Leprol ; 2011 Jan-Feb; 77(1): 78-79
Article Dans Anglais | IMSEAR | ID: sea-140777
19.
Indian J Dermatol Venereol Leprol ; 2010 Jul-Aug; 76(4): 420-422
Article Dans Anglais | IMSEAR | ID: sea-140658
SÉLECTION CITATIONS
Détails de la recherche